Insulin Aspart in the Management of Diabetes Mellitus: 15 Years of Clinical Experience

Drugs

Volumn 76, Issue 1, 2016, Pages 41-74

  Hermansen, Kjeld ^a   Bohl, Mette ^a   Schioldan, Anne Grethe ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CROSS REACTING ANTIBODY; HUMAN INSULIN; INCRETIN; INSULIN ANTIBODY; INSULIN ASPART; INSULIN DETEMIR; INSULIN GLULISINE; INSULIN LISPRO; ISOPHANE INSULIN; METFORMIN; PIG INSULIN; SHORT ACTING INSULIN;

AREA UNDER THE CURVE; BLOOD GLUCOSE MONITORING; BODY WEIGHT; CEREBROVASCULAR ACCIDENT; CONCENTRATION AT STEADY-STATE; CONTINUOUS INFUSION; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DOUBLE BLIND PROCEDURE; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG SAFETY; DRUG STABILITY; DRUG TOLERABILITY; GLYCEMIC CONTROL; HEALTH ECONOMICS; HEART INFARCTION; HOSPITAL PATIENT; HUMAN; IN VITRO STUDY; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN INFUSION; INSULIN TREATMENT; ISCHEMIC HEART DISEASE; LIVER FAILURE; MAXIMUM PLASMA CONCENTRATION; META ANALYSIS (TOPIC); METABOLIC CLEARANCE RATE; MILD RENAL IMPAIRMENT; MITOGENICITY; MODERATE RENAL IMPAIRMENT; NOCTURNAL HYPOGLYCEMIA; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OXIDATIVE STRESS; PATIENT SATISFACTION; PERIPHERAL VASCULAR DISEASE; PHASE 4 CLINICAL TRIAL (TOPIC); POSTPRANDIAL STATE; PREGNANCY; PREGNANCY DIABETES MELLITUS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECEPTOR BINDING; REVIEW; SEVERE RENAL IMPAIRMENT; TIME TO MAXIMUM PLASMA CONCENTRATION; TRANSIENT ISCHEMIC ATTACK; COST BENEFIT ANALYSIS; DIABETES MELLITUS; ECONOMICS;

COST-BENEFIT ANALYSIS; DIABETES MELLITUS; DRUG STABILITY; HUMANS; INSULIN ASPART; PATIENT SATISFACTION; QUALITY OF LIFE;

EID: 84953350518     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-015-0500-0     Document Type: Review

References (165)

1. International Diabetes Federation. IDF Diabetes Atlas Update 2013. 6th ed. Available at: http://www.idf.org/diabetesatlas/update-2014. Accessed 11 February 2015.
2. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977-86.
3. Diabetes Control and Complications Trial Research Group. The absence of a glycaemic threshold for development of long-term complications: the perspective of the DCCT. Diabetes. 1996;45:1289-98.
4. DCCT, Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA. 2002;287:2563-9.
5. Nathan DM, Bayless M, Cleary P, Genuth S, Gubitosi-Klug R, Lachin JM, DCCT/EDIC Research Group, et al. Diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: advances and contributions. Diabetes. 2013;62:3976-86.
6. Orchard TJ, Nathan DM, Zinman B, Cleary P, Brillon D, Backlund JY, Writing Group for the DCCT/EDIC Research Group, et al. Association between 7 years of intensive treatment of type 1 diabetes and long-term mortality. JAMA. 2015;313:45-53.
7. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33. Lancet. 1998;352:837-53.
8. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321:405-12.
9. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577-89.
10. Boussageon R, Bejan-Angoulvant T, Saadatian-Elahi M, Lafont S, Bergeonneau C, Kassaï B, et al. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials. BMJ. 2011;343:d4169.
11. Currie CJ, Peters JR, Tynan A, Evans M, Heine RJ, Bracco OL, et al. Survival as a function of HbA(1c) in people with type 2 diabetes: a retrospective cohort study. Lancet. 2010;375:481-9.
12. Dailey G. Overall mortality in diabetes mellitus: where do we stand today? Diabetes Technol Ther. 2011;13(Suppl 1):S65-74.
13. Dailey G. Early and intensive therapy for management of hyperglycemia and cardiovascular risk factors in patients with type 2 diabetes. Clin Ther. 2011;33:665-78.
14. MacIsaac RJ, Jerums G. Intensive glucose control and cardiovascular outcomes in type 2 diabetes. Heart Lung Circ. 2011;20:647-54.
15. Terry T, Raravikar K, Chokrungvaranon N, Reaven PD. Does aggressive glycemic control benefit macrovascular and microvascular disease in type 2 diabetes? Insights from ACCORD, ADVANCE, and VADT. Curr Cardiol Rep. 2012;14:79-88.
16. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38:140-9.
17. Pozzilli P, Strollo R, Bonora E. One size does not fit all glycemic targets for type 2 diabetes. J Diabetes Investig. 2014;5:134-41.
18. Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes Care. 2003;26:881-5.
19. Bonora E, Muggeo M. Postprandial blood glucose as a risk factor for cardiovascular disease in Type II diabetes: the epidemiological evidence. Diabetologia. 2001;44:2107-14.
20. Ceriello A, Taboga C, Tonutti L, Quagliaro L, Piconi L, Bais B, et al. Evidence for an independent and cumulative effect of postprandial hypertriglyceridemia and hyperglycemia on endothelial dysfunction and oxidative stress generation: effects of short- and long-term simvastatin treatment. Circulation. 2002;106:1211-8.
21. Ceriello A, Hanefeld M, Leiter L, Monnier L, Moses A, Owens D, et al. Postprandial glucose regulation and diabetic complications. Arch Intern Med. 2004;164:2090-5.
22. DECODE Study Group, The European Diabetes Epidemiology Group. Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med. 2001;161:397-405.
23. Hanefeld M, Koehler C, Schaper F, Fuecker K, Henkel E, Temelkova-Kurktschiev T. Postprandial plasma glucose is an independent risk factor for increased carotid intima-media thickness in non-diabetic individuals. Atherosclerosis. 1999;144:229-35.
24. Hanefeld M, Temelkova-Kurktschiev T. Control of post-prandial hyperglycemia - an essential part of good diabetes treatment and prevention of cardiovascular complications. Nutr Metab Cardiovasc Dis. 2002;12:98-107.
25. Standl E, Schnell O, Ceriello A. Postprandial hyperglycemia and glycemic variability: should we care? Diabetes Care. 2011;34(Suppl 2):S120-7.
26. Brange J, Owens DR, Kang S, Vølund A. Monomeric insulins and their experimental and clinical implications. Diabetes Care. 1990;13:923-54.
27. Brange J. Design of insulin analogues for meal-related therapy. J Diabetes Complicat. 1993;7:106-12.
28. Rasmussen CH, Røge RM, Ma Z, Thomsen M, Thorisdottir RL, Chen JW, et al. Insulin aspart pharmacokinetics: an assessment of its variability and underlying mechanisms. Eur J Pharm Sci. 2014;62:65-75.
29. Lindholm A. New insulins in the treatment of diabetes mellitus. Best Pract Res Clin Gastroenterol. 2002;16:475-92.
30. Nosek L, Roggen K, Heinemann L, Gottschalk C, Kaiser M, Arnolds S, et al. Insulin aspart has a shorter duration of action than human insulin over a wide dose-range. Diabetes Obes Metab. 2013;15:77-83.
31. Overmann H, Heinemann L. Injection-meal interval: recommendations of diabetologists and how patients handle it. Diabetes Res Clin Pract. 1999;43:137-42.
32. Chapman TM, Noble S, Goa KL. Insulin aspart: a review of its use in the management of type 1 and 2 diabetes mellitus. Drugs. 2002;62:1945-81 (erratum in: Drugs. 2003;63:512).
33. Whittingham JL, Edwards DJ, Antson AA, Clarkson JM, Dodson GG. Interactions of phenol and m-cresol in the insulin hexamer, and their effect on the association properties of B28 pro - > Asp insulin analogues. Biochemistry. 1998;37:11516-23.
34. Drejer K. The bioactivity of insulin analogues from in vitro receptor binding to in vivo glucose uptake. Diabetes Metab Rev. 1992;8:259-85.
35. Lindholm A, Jacobsen LV. Clinical pharmacokinetics and pharmacodynamics of insulin aspart. Clin Pharmacokinet. 2001;40:641-59.
36. Heinemann L, Heise T, Jorgensen LN, Starke AA. Action profile of the rapid acting insulin analogue: human insulin B28Asp. Diabet Med. 1993;10:535-9.
37. Heinemann L, Kapitza C, Starke A, Heise T. Time-action profile of the insulin analogue B28Asp. Diabet Med. 1996;13:683-4.
38. Mudaliar SR, Lindberg FA, Joyce M, Beerdsen P, Strange P, Lin A, et al. Insulin aspart (B28 asp-insulin): a fast-acting analog of human insulin: absorption kinetics and action profile compared with regular human insulin in healthy nondiabetic subjects. Diabetes Care. 1999;22:1501-6.
39. Home PD, Barriocanal L, Lindholm A. Comparative pharmacokinetics and pharmacodynamics of the novel rapid-acting insulin analogue, insulin aspart, in healthy volunteers. Eur J Clin Pharmacol. 1999;55:199-203.
40. Kaku K, Matsuda M, Urae A, Irie S. Pharmacokinetics and pharmacodynamics of insulin aspart, a rapid-acting analog of human insulin, in healthy Japanese volunteers. Diabetes Res Clin Pract. 2000;49:119-26.
41. Lindholm A, McEwen J, Riis AP. Improved postprandial glycaemic control with insulin aspart - a randomized double-blind cross-over trial in type 1 diabetes mellitus. Diabetes Care. 1999;22:801-5.
42. Ma Z, Parkner T, Frystyk J, Laursen T, Lauritzen T, Christiansen JS. A comparison of pharmacokinetics and pharmacodynamics of insulin aspart, biphasic insulin aspart 70, biphasic insulin aspart 50, and human insulin: a randomized, quadruple crossover study. Diabetes Technol Ther. 2012;14:589-95.
43. Ando H, Kurita S, Shimizu A, Kato K, Ishikura K, Taji K, et al. Pharmacokinetics and pharmacodynamics of insulin aspart in patients with type 2 diabetes: assessment using a meal tolerance test under clinical conditions. Clin Exp Pharmacol Physiol. 2012;39:528-34.
44. Perriello G, Pampanelli S, Porcellati F, Avogaro A, Bosi E, Petrella G, et al. Insulin aspart improves meal time glycaemic control in patients with type 2 diabetes: a randomized, stratified, double-blind and cross-over trial. Diabet Med. 2005;22:606-11.
45. Johansson UB, Amsberg S, Hannerz L, Wredling R, Adamson U, Arnqvist HJ, et al. Impaired absorption of insulin aspart from lipohypertrophic injection sites. Diabetes Care. 2005;28:2025-7.
46. Engwerda EE, Abbink EJ, Tack CJ, de Galan BE. Improved pharmacokinetic and pharmacodynamic profile of rapid-acting insulin using needle-free jet injection technology. Diabetes Care. 2011;34:1804-8.
47. Engwerda EE, Tack CJ, de Galan BE. Needle-free jet injection of rapid-acting insulin improves early postprandial glucose control in patients with diabetes. Diabetes Care. 2013;36:3436-41.
48. von Mach MA, Brinkmann C, Hansen T, Weilemann LS, Beyer J. Differences in pharmacokinetics and pharmacodynamics of insulin lispro and aspart in healthy volunteers. Exp Clin Endocrinol Diabetes. 2002;110:416-9.
49. Hedman CA, Lindström T, Arnqvist HJ. Direct comparison of insulin lispro and aspart shows small differences in plasma insulin profiles after subcutaneous injection in type 1 diabetes. Diabetes Care. 2001;24:1120-1.
50. Homko C, Deluzio A, Jimenez C, Kolaczynski JW, Boden G. Comparison of insulin aspart and lispro: pharmacokinetic and metabolic effects. Diabetes Care. 2003;26:2027-31.
51. Plank J, Wutte A, Brunner G, Siebenhofer A, Semlitsch B, Sommer R, et al. A direct comparison of insulin aspart and insulin lispro in patients with type 1 diabetes. Diabetes Care. 2002;25:2053-7.
52. Arnolds S, Rave K, Hövelmann U, Fischer A, Sert-Langeron C, Heise T. Insulin glulisine has a faster onset of action compared with insulin aspart in healthy volunteers. Exp Clin Endocrinol Diabetes. 2010;118:662-4.
53. Bolli GB, Luzio S, Marzotti S, Porcellati F, Sert-Langeron C, Charbonnel B, et al. Comparative pharmacodynamic and pharmacokinetic characteristics of subcutaneous insulin glulisine and insulin aspart prior to a standard meal in obese subjects with type 2 diabetes. Diabetes Obes Metab. 2011;13:251-7.
54. Heinemann L, Weyer C, Rauhaus M, Heinrichs S, Heise T. Variability of the metabolic effect of soluble insulin and the rapid-acting insulin analog insulin aspart. Diabetes Care. 1998;21:1910-4.
55. Rosenfalck A, Thorsby P, Kjems L, Birkeland K, Dejgaard A, Hanssen KF, et al. Improved postprandial glycaemic control with insulin Aspart in type 2 diabetic patients treated with insulin. Acta Diabetologia. 2000;37:41-6.
56. Ohta A, Arai K, Nishine A, Sada Y, Kato H, Fukuda H, et al. Comparison of daily glucose excursion by continuous glucose monitoring between type 2 diabetic patients receiving preprandial insulin aspart or postprandial insulin glulisine. Endocr J. 2013;60:173-7.
57. Gredal C, Rosenfalck AM, Dejgaard A, Hilsted J. Targeting postprandial hyperglycaemia in patients with recently diagnosed type 2 diabetes with a fixed, weight-based dose of insulin Aspart. Scand J Clin Lab Invest. 2008;68:739-44.
58. Tanaka N, Hiura Y. Effects of rapid-acting insulin analogues insulin glulisine and insulin aspart on postprandial glycemic excursion with single bout of exercise in patients with type 2 diabetes. Endocr J. 2015;62:411-6.
59. Krones R, Schütte C, Heise T. The rapid-acting properties of insulin aspart are preserved in elderly people with type 2 diabetes. Diabetes Obes Metab. 2009;11:41-4.
60. Meneilly GS. A comparison of insulin aspart and regular insulin in elderly patients with type 2 diabetes. Diabetes Obes Metab. 2007;9:754-5.
61. Ruan Y, Elleri D, Allen JM, Tauschmann M, Wilinska ME, Dunger DB, et al. Pharmacokinetics of diluted (U20) insulin aspart compared with standard (U100) in children aged 3-6 years with type 1 diabetes during closed-loop insulin delivery: a randomised clinical trial. Diabetologia. 2015;58:687-90.
62. Mortensen H, Lindholm A, Olsen B, Hylleberg B. Rapid appearance and onset of action of insulin aspart in paediatric subjects with type 1 diabetes. Eur J Paediatr. 2000;159:483-8.
63. Petersen SB, Kildegaard J, Nielsen FS, Søndergaard E, Parkner T, Laursen T, et al. Pharmacokinetics following continuous subcutaneous insulin infusion of insulin aspart with or without initial subcutaneous bolus. Diabetes Obes Metab. 2010;12:334-40.
64. Haidar A, Elleri D, Kumareswaran K, Leelarathna L, Allen JM, Caldwell K, et al. Pharmacokinetics of insulin aspart in pump-treated subjects with type 1 diabetes: reproducibility and effect of age, weight, and duration of diabetes. Diabetes Care. 2013;36:e173-4.
65. Ihlo CA, Lauritzen T, Sturis J, Skyggebjerg O, Christiansen JS, Laursen T. Pharmacokinetics and pharmacodynamics of different modes of insulin pump delivery. A randomized, controlled study comparing subcutaneous and intravenous administration of insulin aspart. Diabet Med. 2011;28:230-6.
66. Swan KL, Dziura JD, Steil GM, Voskanyan GR, Sikes KA, Steffen AT, et al. Effect of age of infusion site and type of rapid-acting analog on pharmacodynamic parameters of insulin boluses in youth with type 1 diabetes receiving insulin pump therapy. Diabetes Care. 2009;32:240-4.
67. Holmes G, Galitz L, Hu P, Lyness W. Pharmacokinetics of insulin aspart in obesity, renal impairment, or hepatic impairment. Br J Clin Pharmacol. 2005;60:469-76.
68. Kulozik F, Hasslacher C. Insulin requirements in patients with diabetes and declining kidney function: differences between insulin analogues and human insulin? Ther Adv Endocrinol Metab. 2013;4:113-21.
69. Pettitt DJ, Ospina P, Kolaczynski JW, Jovanovic L. Comparison of an insulin analog, insulin aspart, and regular human insulin with no insulin in gestational diabetes mellitus. Diabetes Care. 2003;26:183-6.
70. Home P, Lindholm A, Riis A, European Insulin Aspart Study Group. Insulin aspart vs. human insulin in the management of long-term blood glucose control in Type 1 diabetes mellitus: a randomized controlled trial. Diabet Med. 2000;17:762-70.
71. Raskin P, Guthrie RA, Leiter L, Riis A, Jovanovic L. Use of insulin aspart, a fast-acting insulin analog, as the mealtime insulin in the management of patients with type 1 diabetes. Diabetes Care. 2000;23:583-8.
72. DeVries JH, Lindholm A, Jacobsen JL, Heine RJ, Home PD, Tri-Continental Insulin Aspart Study Group. A randomized trial of insulin aspart with intensified basal NPH insulin supplementation in people with Type 1 diabetes. Diabet Med. 2003;20:312-8.
73. Home PD, Lindholm A, Hylleberg B, Round P. Improved glycemic control with insulin aspart. A multicenter randomized double-blind crossover trial in type 1 diabetic patients. Diabetes Care. 1998;21:1904-9.
74. Home PD, Hallgren P, Usadel KH, Sane T, Faber J, Grill V, et al. Pre-meal insulin aspart compared with pre-meal soluble human insulin in type 1 diabetes. Diabetes Res Clin Pract. 2006;71:131-9.
75. Tamás G, Marre M, Astorga R, Dedov I, Jacobsen J, Lindholm A, Insulin Aspart Study Goup. Glycaemic control in type 1 diabetic patients using optimised insulin aspart or human insulin in a randomised multinational study. Diabetes Res Clin Pract. 2001;54:105-14.
76. Brock Jacobsen I, Vind BF, Korsholm L, Flyvbjerg A, Frystyk J, Holst JJ, et al. Counter-regulatory hormone responses to spontaneous hypoglycaemia during treatment with insulin Aspart or human soluble insulin: a double-blinded randomized cross-over study. Acta Physiol (Oxf). 2011;202:337-47.
77. Heller SR, Colagiuri S, Vaaler S, Wolffenbuttel BH, Koelendorf K, Friberg HH, et al. Hypoglycaemia with insulin aspart: a double-blind, randomised, crossover trial in subjects with Type 1 diabetes. Diabet Med. 2004;21:769-75.
78. Hermansen K, Fontaine P, Kukolja KK, Peterkova V, Leth G, Gall MA. Insulin analogues (insulin detemir and insulin aspart) vs. traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes. Diabetologia. 2004;47:622-9.
79. Bretzel RG, Arnolds S, Medding J, Linn T. A direct efficacy and safety comparison of insulin aspart, human soluble insulin, and human premix insulin (70/30) in patients with type 2 diabetes. Diabetes Care. 2004;27:1023-7.
80. Gallagher A, Home PD. The effect of improved post-prandial blood glucose control on post-prandial metabolism and markers of vascular risk in people with Type 2 diabetes. Diabetes Res Clin Pract. 2005;67:196-203.
81. Herrmann BL, Kasser C, Keuthage W, Huptas M, Dette H, Klute A. Comparison of insulin aspart vs. regular human insulin with or without insulin detemir concerning adipozytokines and metabolic effects in patients with type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes. 2013;121:210-3.
82. Pala L, Mannucci E, Dicembrini I, Rotella CM. A comparison of mealtime aspart and human insulin in combination with metformin in type 2 diabetes patients. Diabetes Res Clin Pract. 2007;78:132-5.
83. Raslová K, Bogoev M, Raz I, Leth G, Gall MA, Hâncu N. Insulin detemir and insulin aspart: a promising basal-bolus regimen for type 2 diabetes. Diabetes Res Clin Pract. 2004;66:193-201 (erratum in: Diabetes Res Clin Pract. 2006;72:112).
84. Chlup R, Zapletalová J, Seckar P, Malá E, Doubravová B, Táncosová S, et al. Benefits of complementary therapy with insulin aspart versus human regular insulin in persons with type 2 diabetes mellitus. Diabetes Technol Ther. 2007;9:223-31.
85. Krzymień J, Kobli T, Nazar M. Multicenter, open-label, nonrandomized, observational safety study in subjects using insulin aspart in basal-bolus regimen for the treatment of diabetes. Pol Arch Med Wewn. 2010;120:444-50.
86. Gallagher A, Butler TJ, Home PD. The effect of the optimal use of rapid-acting insulin analogues on insulin secretion in Type 2 diabetes. Diabetes Res Clin Pract. 2007;76:327-34.
87. Latif ZA, Hussein Z, Litwak L, El Naggar N, Chen JW, Soewondo P. Safety and effectiveness of insulin aspart in basal-bolus regimens regardless of age: a1chieve study results. Diabetes Ther. 2013;4:103-18.
88. Randeree H, Liebl A, Hajjaji I, Khamseh M, Zajdenverg L, Chen JW, et al. Safety and effectiveness of bolus insulin aspart in people with type 2 diabetes: A1chieve sub-analysis. Diabetes Ther. 2013;4:153-66.
89. Cucinotta D, Caputo S, Mannucci E, Nicolucci A, Pellegrini F, Perriello G, et al. Safety and efficacy of insulin aspart and soluble human insulin in Type 2 diabetes mellitus. Minerva Endocrinol. 2012;37:357-66.
90. Heller S, Bode B, Kozlovski P, Svendsen AL. Meta-analysis of insulin aspart versus regular human insulin used in a basal-bolus regimen for the treatment of diabetes mellitus. J Diabetes. 2013;5:482-91.
91. Meneghini L, Mersebach H, Kumar S, Svendsen AL, Hermansen K. Comparison of 2 intensification regimens with rapid-acting insulin aspart in type 2 diabetes mellitus inadequately controlled by once-daily insulin detemir and oral diabetes drugs: the step-wise randomized study. Endocr Pract. 2011;5:727-36.
92. Rodbard HW, Visco VE, Andersen H, Hiort LC, Shu DH. Treatment intensification with stepwise addition of prandial insulin aspart boluses compared with full basal-bolus therapy (FullSTEP Study): a randomised, treat-to-target clinical trial. Lancet Diabetes Endocrinol. 2014;2:30-7.
93. Rathmann W, Kostev K. Lower incidence of recorded cardiovascular outcomes in patients with type 2 diabetes using insulin aspart vs. those on human regular insulin: observational evidence from general practices. Diabetes Obes Metab. 2013;15:358-63.
94. Naruse R, Takebayashi K, Morita K, Aso Y, Inukai T. Comparison of effects of insulin aspart three times a day versus insulin detemir once a day on oxidative stress in patients with type 2 diabetes. Endocr J. 2011;58:1055-63.
95. Danne T, Aman J, Schober E, Deiss D, Jacobsen JL, Friberg HH, et al. A comparison of postprandial and preprandial administration of insulin aspart in children and adolescents with type 1 diabetes. Diabetes Care. 2003;26:2359-64.
96. Danne T, Råstam J, Odendahl R, Näke A, Schimmel U, Szczepanski R, et al. Parental preference of prandial insulin aspart compared with preprandial human insulin in a basal-bolus scheme with NPH insulin in a 12-wk crossover study of preschool children with type 1 diabetes. Pediatr Diabetes. 2007;5:278-85.
97. Cemeroglu AP, Kleis L, Wood A, Parkes C, Wood MA, Davis AT. Comparison of the effect of insulin glulisine to insulin aspart on breakfast postprandial blood glucose levels in children with type 1 diabetes mellitus on multiple daily injections. Endocr Pract. 2013;19:614-9.
98. Pańkowska E, Nazim J, Szalecki M, Urban M. Equal metabolic control but superior caregiver treatment satisfaction with insulin aspart in preschool children. Diabetes Technol Ther. 2010;12:413-8.
99. Skogsberg L, Fors H, Hanas R, Chaplin JE, Lindman E, Skogsberg J. Improved treatment satisfaction but no difference in metabolic control when using continuous subcutaneous insulin infusion vs. multiple daily injections in children at onset of type 1 diabetes mellitus. Pediatr Diabetes. 2008;9:472-9.
100. Rostami P, Setoodeh A, Rabbani A, Nakhaei-Moghadam M, Najmi-Varzaneh F, Rezaei N. A randomized clinical trial of insulin glargine and aspart, compared to NPH and regular insulin in children with Type 1 diabetes mellitus. Iran J Pediatr. 2014;24:173-8.
101. Cherubini V, Iannilli A, Iafusco D, Cardella F, Giamprini MS, Fanelli C, et al. Premeal insulin treatment during basal-bolus regimen in young children with type 1 diabetes. Diabetes Care. 2006;29:2311-2.
102. Macintosh MC, Fleming KM, Bailey JA, Doyle P, Modder J, Acolet D, et al. Perinatal mortality and congenital anomalies in babies of women with type 1 or type 2 diabetes in England, Wales, and Northern Ireland: population based study. BMJ. 2006;333:177.
103. Middleton P, Crowther CA, Simmonds L. Different intensities of glycaemic control for pregnant women with pre-existing diabetes. Cochrane Database Syst Rev. 2012;8:CD008540.
104. Mathiesen ER, Kinsley B, Amiel SA, Heller S, McCance D, Duran S, et al. Maternal glycemic control and hypoglycemia in type 1 diabetic pregnancy: a randomized trial of insulin aspart versus human insulin in 322 pregnant women. Diabetes Care. 2007;30:771-6.
105. Pettitt DJ, Ospina P, Howard C, Zisser H, Jovanovic L. Efficacy, safety and lack of immunogenicity of insulin aspart compared with regular human insulin for women with gestational diabetes mellitus. Diabet Med. 2007;24:1129-35.
106. Moghissi ES, Korytkowski MT, DiNardo M, Einhorn D, Hellman R, Hirsch IB, et al. American Association of Clinical Endocrinologists and American Diabetes Association consensus statement on inpatient glycemic control. Endocr Pract. 2009;15:353-69.
107. Umpierrez GE, Cuervo R, Karabell A, Latif K, Freire AX, Kitabchi AE. Treatment of diabetic ketoacidosis with subcutaneous insulin aspart. Diabetes Care. 2004;27:1873-8.
108. Moghissi ES. Addressing hyperglycemia from hospital admission to discharge. Curr Med Res Opin. 2010;26:589-98.
109. Udwadia F, Bhattacharyya A, Seshiah V, Sethi BK, Kumar S, Subbanna PK, et al. Intravenous insulin aspart in a hospital setting: results from an observational study examining patient outcomes and physician preferences. Diabetes Manag. 2012;2:103-10.
110. Bernard JB, Munoz C, Harper J, Muriello M, Rico E, Baldwin D. Treatment of inpatient hyperglycemia beginning in the emergency department: a randomized trial using insulins aspart and detemir compared with usual care. J Hosp Med. 2011;6:279-84.
111. Umpierrez GE, Hor T, Smiley D, Temponi A, Umpierrez D, Ceron M, et al. Comparison of inpatient insulin regimens with detemir plus aspart versus neutral protamine Hagedorn plus regular in medical patients with type 2 diabetes. J Clin Endocrinol Metab. 2009;94:564-9.
112. Bergenstal RM, Tamborlane WV, Ahmann A, Buse JB, Dailey G, Davis SN, et al. Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. N Engl J Med. 2010;363:311-20.
113. Doyle EA, Weinzimer SA, Steffen A, Ahern JA, Vincent M, Tamborlane WV. A randomized, prospective trial comparing the efficacy of continuous subcutaneous insulin infusion with multiple daily injections using insulin glargine. Diabetes Care. 2004;27:1554-8.
114. Gao GQ, Heng XY, Wang YL, Li WX, Dong QY, Liang CG, et al. Comparison of continuous subcutaneous insulin infusion and insulin glargine-based multiple daily insulin aspart injections with preferential adjustment of basal insulin in patients with type 2 diabetes. Exp Ther Med. 2014;8:1191-6.
115. Hirsch IB, Bode BW, Garg S, Lane WS, Sussman A, Hu P, et al. Continuous subcutaneous insulin infusion (CSII) of insulin aspart vs. multiple daily injection of insulin aspart/insulin glargine in type 1 diabetic patients previously treated with CSII. Diabetes Care. 2005;28:533-8.
116. Kawamura T, Urakami T, Sugihara S, Kim HS, Mochizuki M, Amamiya S. Changes in glycemic control and quality of life in pediatric type 1 diabetics with continuous subcutaneous insulin infusion of insulin aspart following multiple daily injection therapy. Clin Pediatr Endocrinol. 2008;17:39-47.
117. Raskin P, Bode BW, Marks JB, Hirsch IB, Weinstein RL, McGill JB, et al. Continuous subcutaneous insulin infusion and multiple daily injection therapy are equally effective in type 2 diabetes: a randomized, parallel-group, 24-week study. Diabetes Care. 2003;26:2598-603.
118. Lv WS, Li L, Wen JP, Pan RF, Sun RX, Wang J, et al. Comparison of a multiple daily insulin injection regimen (glargine or detemir once daily plus prandial insulin aspart) and continuous subcutaneous insulin infusion (aspart) in short-term intensive insulin therapy for poorly controlled type 2 diabetes patients. Int J Endocrinol. 2013;2013:614242.
119. DeVries JH, Snoek FJ, Kostense PJ, Masurel N, Heine RJ, Dutch Insulin Pump Study Group. A randomized trial of continuous subcutaneous insulin infusion and intensive injection therapy in type 1 diabetes for patients with long-standing poor glycemic control. Diabetes Care. 2002;25:2074-80.
120. Bode B, Strange P. Efficacy, safety and pump compatibility of insulin aspart used in continuous subcutaneous insulin infusion therapy in patients with Type 1 diabetes. Diabetes Care. 2001;24:69-72.
121. Bode B, Weinstein R, Bell D, McGill J, Nadeau D, Raskin P, et al. Comparison of insulin aspart with buffered regular insulin and insulin lispro in continuous subcutaneous insulin infusion: a randomized study in type 1 diabetes. Diabetes Care. 2002;25:439-44.
122. Chlup R, Zapletalova J, Seckar P, Chlupová L, Táncosová S, Reznícková M. Benefits of insulin aspart vs phosphate-buffered human regular insulin in persons with type 1 diabetes treated by means of an insulin pump. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2004;148:27-32.
123. Bi YF, Zhao LB, Li XY, Wang WQ, Sun SY, Chen YH, et al. A 2-way cross-over, open-labeled trial to compare efficacy and safety of insulin Aspart and Novolin R delivered with CSII in 21 Chinese diabetic patients. Chin Med J (Engl). 2007;120:1700-3.
124. Alemzadeh R, Palma-Sisto P, Holzum M, Parton E, Kicher J. Continuous subcutaneous insulin infusion attenuated glycemic instability in preschool children with type 1 diabetes mellitus. Diabetes Technol Ther. 2007;9:339-47.
125. Dzygalo K, Szypowska A. Impact of insulins glulisine and aspart on postprandial glycemia after a high-glycemic index meal in children with type 1 diabetes. Eur J Endocrinol. 2014;170:539-45.
126. Thrasher J, Bhargava A, Rees TM, Wang T, Guzman CB, Glass LC. Using insulin lispro with continuous subcutaneous insulin infusion is safe and effective in patients with type 2 diabetes: a randomized crossover trial of insulin lispro versus insulin aspart. Endocr Pract. 2014;4:1-28.
127. van Bon AC, Bode BW, Sert-Langeron C, et al. Insulin glulisine compared to insulin aspart and to insulin lispro administered by continuous subcutaneous insulin infusion in patients with type 1 diabetes: a randomized controlled trial. Diabetes Technol Ther. 2011;13:607-14.
128. Weinzimer SA, Ternand C, Howard C, Chang CT, Becker DJ, Laffel LM, et al. A randomized trial comparing continuous subcutaneous insulin infusion of insulin aspart versus insulin lispro in children and adolescents with type 1 diabetes. Diabetes Care. 2008;31:210-5.
129. Wittlin SD, Marcus AO, Weng CS, Howard CP, Schorr AB, CONTROL Study Group. Evaluation of treatment satisfaction associated with the use of insulin aspart in continuous subcutaneous insulin infusion. Diabetes Technol Ther. 2008;10:1-10.
130. Tamborlane WV, Renard E, Wadwa RP, Blevins T, Jacober SJ, Liu R, et al. Glycemic control after 6 days of insulin pump reservoir use in type 1 diabetes: results of double-blind and open-label cross-over trials of insulin lispro and insulin aspart. J Diabetes. 2015;7:270-8.
131. Bartolo PD, Pellicano F, Scaramuzza A, Sardu C, Casetti T, Bosi E, et al. Better postprandial glucose stability during continuous subcutaneous infusion with insulin aspart compared with insulin lispro in patients with type 1 diabetes. Diabetes Technol Ther. 2008;10:495-8.
132. Brunner G, Hirschberger S, Sendlhofer G. Postprandial administration of the insulin analogue insulin aspart in patients with type 1 diabetes mellitus. Diabet Med. 2000;17:371-5.
133. Luijf YM, van Bon AC, Hoekstra JB, Devries JH. Premeal injection of rapid-acting insulin reduces postprandial glycemic excursions in type 1 diabetes. Diabetes Care. 2010;33:2152-5.
134. Bott U, Ebrahim S, Hirschberger S, Skovlund SE. Effect of the insulin analogue insulin aspart on quality-of-life and treatment satisfaction in type 1 diabetic patients. Diabet Med. 2003;20:626-34.
135. Kurtzhals P, Schäffer L, Sørensen A, Kristensen C, Jonassen I, Schmid C, et al. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes. 2000;49:999-1005.
136. Ma Z, Christiansen JS, Laursen T, Wu C, Lauritzen T, Parkner T, et al. Effects of human insulin and insulin aspart preparations on levels of IGF-I, IGFBPs and IGF bioactivity in patients with type 1 diabetes. BMC Endocr Disord. 2014;14:35.
137. Hattori N, Duhita MR, Mukai A, Matsueda M, Shimatsu A. Development of insulin antibodies and changes in titers over a long-term period in patients with type 2 diabetes. Clin Chim Acta. 2014;433:135-8.
138. Lindholm A, Jensen LB, Home PD, Raskin P, Boehm BO, Råstam J. Immune responses to insulin aspart and biphasic insulin aspart in people with type 1 and type 2 diabetes. Diabetes Care. 2002;25:876-82.
139. McCance DR, Damm P, Mathiesen ER, Hod M, Kaaja R, Dunne F, et al. Evaluation of insulin antibodies and placental transfer of insulin aspart in pregnant women with type 1 diabetes mellitus. Diabetologia. 2008;51:2141-3.
140. Holmberg H, Mersebach H, Kanc K, Ludvigsson J, Insulin Aspart Study Group on Immunogenicity. Antibody response to insulin in children and adolescents with newly diagnosed Type 1 diabetes. Diabet Med. 2008;25:792-7.
141. Hod M, Damm P, Kaaja R, Visser GH, Dunne F, Demidova I, et al. Fetal and perinatal outcomes in type 1 diabetes pregnancy: a randomized study comparing insulin aspart with human insulin in 322 subjects. Am J Obstet Gynecol. 2008;198(186):e1-7.
142. Frier BM, Ewing FM, Lindholm A, Hylleberg B, Kanc K. Symptomatic and counterregulatory hormonal responses to acute hypoglycaemia induced by insulin aspart and soluble human insulin in Type 1 diabetes. Diabetes Metab Res Rev. 2000;16:262-8.
143. Gao Y, Pan CY, Zou DJ, Xu ZR, Liu XM, Guo XH. Postprandial glycemic control using insulin aspart with NPH in inadequately controlled diabetics. Zhonghua Yi Xue Za Zhi. 2009;98:1960-3.
144. Kristensen PL, Pedersen-Bjergaard U, Beck-Nielsen H, Nørgaard K, Perrild H, Christiansen JS, et al. A prospective randomised cross-over study of the effect of insulin analogues and human insulin on the frequency of severe hypoglycaemia in patients with type 1 diabetes and recurrent hypoglycaemia (the HypoAna trial): study rationale and design. BMC Endocr Disord. 2012;12:10.
145. Pedersen-Bjergaard U, Kristensen PL, Beck-Nielsen H, Nørgaard K, Perrild H, Christiansen JS, et al. Effect of insulin analogues on risk of severe hypoglycaemia in patients with type 1 diabetes prone to recurrent severe hypoglycaemia (HypoAna trial): a prospective, randomised, open-label, blinded-endpoint crossover trial. Lancet Diabetes Endocrinol. 2014;2:553-61.
146. Swanson CM, Potter DJ, Kongable GL, Cook CB. Update on inpatient glycemic control in hospitals in the United States. Endocr Pract. 2011;17:853-61.
147. Umpierrez GE, Isaacs SD, Bazargan N, You X, Thaler LM, Kitabchi AE. Hyperglycemia: an independent marker of in-hospital mortality in patients with undiagnosed diabetes. J Clin Endocrinol Metab. 2002;87:978-82.
148. Dungan KM, Sagrilla C, Abdel-Rasoul M, Osei K. Prandial insulin dosing using the carbohydrate counting technique in hospitalized patients with type 2 diabetes. Diabetes Care. 2013;36:3476-82.
149. Chawla M, Malve H, Shah H, Shinde S, Bhoraskar A. Safety of intravenous insulin aspart compared to regular human insulin in patients undergoing ICU monitoring post cardiac surgery: an Indian experience. J Diabetes Metab Disord. 2015;14:20.
150. Senstius J, Harboe E, Westermann H. In-vitro stability of insulin aspart in simulated continuous subcutaneous insulin infusion using a MiniMed 508 insulin pump. Diabetes Technol Ther. 2007;9:75-9.
151. Senstius J, Poulsen C, Hvass A. Comparison of in vitro stability for insulin aspart and insulin glulisine during simulated use in infusion pumps. Diabetes Technol Ther. 2007;9:517-21.
152. Senesh G, Bushi D, Neta A, Yodfat O. Compatibility of insulin Lispro, Aspart, and Glulisine with the Solo MicroPump, a novel miniature insulin pump. J Diabetes Sci Technol. 2010;4:104-10.
153. Woods RJ, Alarcón J, McVey E, Pettis RJ. Intrinsic fibrillation of fast-acting insulin analogs. J Diabetes Sci Technol. 2012;6:265-76.
154. Poulsen C, Langkjaer L, Worsøe C. Precipitation of insulin products used for continuous subcutaneous insulin infusion. Diabetes Technol Ther. 2005;7:142-50.
155. Poulsen C, Langkjaer L, Worsøe C. Precipitation of insulin aspart and insulin glulisine products used for continuous subcutaneous insulin infusion. Diabetes Technol Ther. 2007;9:26-35.
156. Kerr D, Morton J, Whatley-Smith C, Everett J, Begley JP. Laboratory-based non-clinical comparison of occlusion rates using three rapid- acting insulin analogs in continuous subcutaneous insulin infusion catheters using low flow rates. J Diabetes Sci Technol. 2008;2:450-5.
157. Naik S, Kerr D, Begley J, Morton J. Influence of local skin temperature and choice of insulin analog on catheter occlusion rates during continuous insulin infusion: an exploratory study. Diabetes Technol Ther. 2012;14:1018-22.
158. Pickup JC, Sutton AJ. Severe hypoglycaemia and glycaemic control in Type 1 diabetes: meta-analysis of multiple daily insulin injections compared with continuous subcutaneous insulin infusion. Diabet Med. 2008;25:765-74.
159. Lloyd A, Townsend C, Munro V, Twena N, Nielsen S, Holman A. Cost-effectiveness of insulin aspart compared to human insulin in pregnant women with type 1 diabetes in the UK. Curr Med Res Opin. 2009;25:599-605.
160. Liebl A, Seitz L, Palmer AJ. Health Economics Analysis of Insulin Aspart vs. Regular Human Insulin in Type 2 Diabetes Patients, Based on Observational Real life Evidence from General Practices in Germany. Exp Clin Endocrinol Diabetes. 2014;122:517-22.
161. Palmer JL, Goodall G, Nielsen S, Kotchie RW, Valentine WJ, Palmer AJ, et al. Cost-effectiveness of insulin aspart versus human soluble insulin in type 2 diabetes in four European countries: subgroup analyses from the PREDICTIVE study. Curr Med Res Opin. 2008;24:1417-28.
162. Aagren M, Luo W, Moës E. Healthcare utilization changes in relation to treatment intensification with insulin aspart in patients with type 2 diabetes. Data from a large US managed-care organization. J Med Econ. 2010;13:16-22.
163. Saunders R, Lian J, Karolicki B, Valentine W. The cost-effectiveness and budget impact of stepwise addition of bolus insulin in the treatment of type 2 diabetes: evaluation of the FullSTEP trial. J Med Econ. 2014;17:827-36.
164. Heise T, Hövelmann U, Brøndsted L, Adrian CL, Nosek L, Haahr H. Faster-acting insulin aspart: earlier onset of appearance and greater early pharmacokinetic and pharmacodynamic effects than insulin aspart. Diabetes Obes Metab. 2015;17:682-8.
165. Bode B, Hyveled L, Tamner SC, Ybanez P, Demissie M. Improved post-prandial control with faster-acting insulin aspart in subjects with type 1 diabetes using CSII. Diabetes. 2015;38(Suppl 1):A235.